{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022335","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.935388+00:00","generated_at":"2026-06-22T05:37:37.672086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rallybio Q3 net loss widens to $18.4M; positive RLYB116 Phase 1 data with >99% C5 reduction","bullets":["Net loss $18.4M for Q3 2022, vs $10.2M for Q3 2021; net loss per share $0.60.","Cash, cash equivalents, and marketable securities $132.4M as of Sep 30, 2022; runway into Q1 2024.","RLYB212 Phase 1b shows rapid elimination of transfused platelets; proof-of-concept data expected Q1 2023.","RLYB116 Phase 1: >99% reduction in free C5 within 24 hrs at 100 mg SC; half-life >300 hrs; MAD study in Q1 2023.","R&D expenses $12.1M (up 142% YoY) driven by RLYB212 and RLYB116 development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022335","json":"https://secwatch.observer/filing/0000950170-22-022335.json","markdown":"https://secwatch.observer/filing/0000950170-22-022335.md","text":"https://secwatch.observer/filing/0000950170-22-022335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/0000950170-22-022335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/rlyb-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:37:37.672086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54e07af050f8b89a8051453e0a7b81b8ef323a6a","claim":"Rallybio Corp reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 7, 2022, Rallybio Corporation issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/0000950170-22-022335-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}